Today: 29 April 2026
Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring
31 December 2025
1 min read

Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring

NEW YORK, December 31, 2025, 04:32 ET — Premarket

  • Profusa shares were down about 12% in premarket trading after a sharp rally a day earlier.
  • The microcap said it reworked convertible debt terms, lifting the conversion floor to $0.35 a share.
  • A recent filing outlined conditions for up to $5 million in additional note financing.

Profusa Inc shares were down about 12% at 10.7 cents in premarket trading on Wednesday, after soaring 78% to 12.2 cents in the prior session as investors reacted to the company’s debt restructuring. Tuesday’s session saw the stock trade between 10.8 cents and 17 cents, with volume jumping to about 822 million shares.

The moves matter because Profusa is a thinly traded, penny-stock name where small shifts in financing terms can dominate price action. For existing shareholders, the central question is dilution — how many new shares might be created if lenders convert debt into stock.

Profusa said it restructured its senior secured convertible notes — essentially a loan backed by collateral that can be exchanged for equity — to give it more repayment flexibility and limit potential dilution from conversions. The company said the amended notes increase the conversion floor price to $0.35 from $0.10 and eliminate mandatory amortization payments that had been scheduled to start in the first quarter of 2026.

“We restructured our Senior Secured Convertible Notes for greater repayment flexibility and lower dilution,” Chief Financial Officer Fred Knechtel said. Stock Titan

The company also said mandatory payments tied to its equity line of credit, or ELOC — a financing arrangement that lets a company sell shares over time — increased to 33% under its existing registration statement and to 50% for shares issued under any new Form S-1 registration statement filed after the amendment.

A filing showed Profusa also amended its securities purchase agreement, setting out a path for purchasers to buy up to an additional $5 million of notes, subject to conditions including the prior tranches being reduced to zero, effectiveness of a registration statement for conversion shares, and receipt of stockholder approval. The filing also referenced a reverse stock split expected to be presented to stockholders in January 2026.

For traders, the immediate watch is whether Tuesday’s momentum holds once the regular session opens, after the steep premarket pullback. With the stock still far below the new $0.35 conversion floor, the rally’s durability may hinge on whether investors see the revised terms as reducing near-term dilution risk.

Investors are also likely to focus on the financing “gates” in the filing — particularly the conditions around Nasdaq listing status, registration effectiveness, and shareholder approval — since those determine whether Profusa can access additional capital on the amended terms.

Stock Market Today

  • Align Technology Beats Q1 Sales Estimates, Reports $1.04 Billion Revenue
    April 29, 2026, 4:41 PM EDT. Align Technology (NASDAQ:ALGN) reported a strong Q1 CY2026 with 6.2% year-on-year sales growth to $1.04 billion, exceeding Wall Street revenue estimates by 1.8%. Adjusted earnings per share came in at $2.58, 12.8% above analyst consensus. The company's operating income also beat expectations by 11.1%, driven by solid operating margins of 21.5%. Despite these gains, Align projected next quarter revenue around $1.05 billion, aligning with market forecasts. The company's five-year annualized revenue growth of 7.8% outpaces healthcare sector averages, but recent two-year growth has slowed to 2.3%, raising concerns about demand trends. Analysts project modest growth going forward, around 3%, indicating cautious investor sentiment on new product impact.

Latest article

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

29 April 2026
Nebius Group N.V. shares rose 5.3% to $142.73 Wednesday as Meta Platforms raised its 2026 capital spending forecast by up to $10 billion, citing higher data center costs. Nebius has a contract to supply Meta with up to $27 billion in AI cloud capacity. Fourth-quarter 2025 revenue jumped 547% to $227.7 million, but the company reported a net loss of $249.6 million.
Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

29 April 2026
Phillips 66 reported an adjusted first-quarter profit of $200 million, or 49 cents per share, beating analyst forecasts of a loss. Strong refining margins and 95% plant utilization offset $839 million in hedge-related losses. Shares rose over 6% after the results. The company also completed its acquisition of Lindsey Oil Refinery assets in the UK.
Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

29 April 2026
Extreme Networks shares surged 28% after reporting fiscal Q3 revenue of $316.9 million, up 11%, and non-GAAP earnings of 26 cents per share, both above estimates. The company forecast Q4 revenue of $330–$335 million, topping FactSet’s $326.9 million estimate. SaaS annual recurring revenue rose 28.6% to $236.4 million. Net income climbed to $10.6 million from $3.5 million a year earlier.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Previous Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading
Next Story

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading

Go toTop